SCHEMBL6008133

SCHEMBL6008133

CN([C]=O)n1c2ccccc2c2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.44
POLB P06746 1/20 0.42
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
DNM1 Q05193 2/20 0.37
TSPO P30536 2/20 0.37
KDM4E B2RXH2 3/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ALDH1A1 P00352 3/20 0.35
MAPT P10636 2/20 0.35
HTT P42858 2/20 0.35
LMNA P02545 1/20 0.35
PABPC1 P11940 1/20 0.35
SLC6A2 P23975 1/20 0.35
PER2 O15055 1/20 0.35
CRY1 Q16526 1/20 0.35
CRY2 Q49AN0 1/20 0.35
ALKBH5 Q6P6C2 1/20 0.34
FTO Q9C0B1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6007893 0.78 GPR3 (0.44) GPR3POLBCYP1A2CYP2C19DNM1
SCHEMBL19154998 0.74 GPR3 (0.55) GPR3POLBCYP1A2CYP2C19DNM1
SCHEMBL6006426 0.71 SLC6A2 (0.46) POLBCYP1A2KDM4EL3MBTL1ALDH1A1
SCHEMBL6005012 0.68 SLC6A2 (0.50) L3MBTL1ALDH1A1HTTLMNASLC6A2
SCHEMBL18917484 0.68 GPR3 (0.52) GPR3POLBCYP1A2CYP2C19DNM1
SCHEMBL27559486 0.67 CYP3A4 (0.38) GPR3POLBDNM1TSPOKDM4E
SCHEMBL3301059 0.67 GPR3 (0.46) GPR3POLBCYP1A2CYP2C19KDM4E
SCHEMBL6006476 0.66 SMN1; SMN2 (0.44) POLBL3MBTL1ALDH1A1MAPTHTT
SCHEMBL6006907 0.66 SLC9A1 (0.47) POLBCYP1A2KDM4EATMALDH1A1
SCHEMBL29321 0.63 GPR3 (1.00) GPR3CYP1A2CYP2C19KDM4EATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 GPR3 577/4885POLB 4662/4885CYP1A2 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.